Biogen (BIIB) Depreciation & Amortization (CF) (2009 - 2026)

Biogen (BIIB) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $204.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 11.57% year-over-year to $204.4 million; the TTM figure through Mar 2026 stood at $801.1 million (up 13.01% YoY), while the FY2025 annual figure was $779.9 million, up 15.85% from the prior year.
• Depreciation & Amortization (CF) came in at $204.4 million for Q1 2026 at Biogen, up from $200.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $204.4 million in Q1 2026, with the low at $112.3 million in Q1 2023.
• Average Depreciation & Amortization (CF) over 5 years is $157.1 million, with a median of $147.5 million recorded in 2024.
• Across the five-year window, Depreciation & Amortization (CF) slipped 21.52% in 2023 and soared 46.24% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $119.8 million in 2022, then climbed by 16.94% to $140.1 million in 2023, then soared by 31.33% to $184.0 million in 2024, then advanced by 8.8% to $200.2 million in 2025, then climbed by 2.1% to $204.4 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $204.4 million, $200.2 million, and $202.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.